Embecta Beats Q4 EPS Expectations as Sales Miss and Debt Declines

Overview

• For the quarter ended Sept. 30, Embecta posted $26.4 million in profit on $264 million in sales, with GAAP EPS of 45¢ and adjusted EPS of 50¢ that topped estimates by 4¢.
• Sales came in slightly below the roughly $265.7 million Wall Street consensus, reflecting advanced distributor orders tied to a potential U.S. port strike and July 4 timing plus softer demand in China.
• The company paid down $72.4 million on its term loan during the quarter, bringing 2025 debt reduction to about $184.5 million versus a $110 million target.
• Preliminary fiscal 2026 guidance calls for $1.071 billion to $1.093 billion in sales and adjusted EPS of $2.80 to $3.00.
• Embecta advanced its GLP-1 plan with more than 30 pharma collaborators and inclusion of its pen needles in partner regulatory submissions, while continuing a global brand transition targeted for substantial completion by the end of 2026.